Previous close | 46.50 |
Open | 52.60 |
Bid | 50.25 |
Ask | 53.60 |
Strike | 960.00 |
Expiry date | 2024-11-15 |
Day's range | 49.86 - 52.60 |
Contract range | N/A |
Volume | |
Open interest | 80 |
Automated pumps are already used by about 40% of those with the autoimmune version of diabetes, known as Type-1.
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Assuming the rosier expectations will positively unfold, a reality check is done to compare the current valuation to informative financial ratios